Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cytotherapy is Scopus-indexed (Q1, CiteScore 6.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier B.V..
Checked against the index lists dated .
ISSN 1465-3249Verify ISSN ↗1477-2566Verify ISSN ↗
Publisher: Elsevier B.V.
Cost to publish: About US$3,300 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Transplantation | 10 / 55 | 82nd | Q1 |
| Oncology | 93 / 428 | 78th | Q1 |
| Genetics (clinical) | 27 / 100 | 73rd | Q2 |
| Immunology and Allergy | 78 / 234 | 66th | Q2 |
| Immunology | 85 / 243 | 65th | Q2 |
| Cancer Research | 85 / 233 | 63rd | Q2 |
| Cell Biology | 123 / 289 | 57th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1999–present, best quartile Q1, CiteScore 6.4.
Cytotherapy is Q1 in Transplantation (rank 10 of 55), Q1 in Oncology (rank 93 of 428) and Q2 in Genetics (clinical) (rank 27 of 100), by CiteScore 2025. It is ranked in 7 subject areas in all.
Cytotherapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.4, which places it in quartile Q1 at the 82nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.249, quartile Q1, with an H-index of 115.
The publisher lists an article processing charge of about US$3,300 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cytotherapy is published by Elsevier B.V. Its print ISSN is 1465-3249 and its online ISSN is 1477-2566.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cytotherapy has an h-index of 127 and a 2-year mean of 1.08 citations per paper (OpenAlex). Its Scopus CiteScore is 6.4, quartile Q1. On 2-year citations it ranks #28 of 53 Scopus journals in Transplantation.
Cytotherapy published 755 papers in 2025; its busiest recent year was 2023 with 783. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 75 research articles (2026), authors are most often from United States (38.8%), Japan (9.6%) and China (4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 8 retracted papers are recorded (0.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.